CA Patent

CA3256645A1 — Cyclic compound having selective kras inhibitory effect on hras and nras

Assigned to Chugai Pharmaceutical Co Ltd · Expires 2025-04-23 · 1y expired

What this patent protects

Cyclic compounds that selectively inhibit KRAS were found. Moreover, cyclic compounds were found to interact with an amino acid residue specific to KRAS.

USPTO Abstract

Cyclic compounds that selectively inhibit KRAS were found. Moreover, cyclic compounds were found to interact with an amino acid residue specific to KRAS.

Drugs covered by this patent

Patent Metadata

Patent number
CA3256645A1
Jurisdiction
CA
Classification
—
Expires
2025-04-23
Drug substance claim
No
Drug product claim
No
Assignee
Chugai Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.